Executed License Agreement & Transaction Update

AI SummaryClose X

Roquefort Therapeutics plc has entered into a binding exclusive license agreement for AO-252, a clinical-stage oncology asset targeting TACC3, with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. This transaction involves an upfront consideration of £25.5 million satisfied by the issue of ordinary shares, a move to the AIM market, and a placing to raise a minimum of £10.5 million. The company anticipates multiple near-term value inflection points and proposes to change its name to Coiled Therapeutics plc upon completion. Deferred consideration shares may be issued if market capitalization targets of £60 million, £90 million, or £120 million are met. The license includes milestone payments of up to US$12 million and royalties of up to 4% on net sales.

Disclaimer*

UK 100

Latest directors dealings